Skip to main content
Figure 1 | Breast Cancer Research

Figure 1

From: Estrogen receptor mutations and their role in breast cancer progression

Figure 1

Evolution of ESR1 mutations in estrogen receptor-positive breast cancer with endocrine therapy treatment. ESR1 mutations are rare or nonexistent in primary breast tumors and are significantly enriched in metastatic, endocrine therapy-resistant breast cancer. Nearly all ESR1 mutations localize to the ligand-binding domain (LBD) of the estrogen receptor (ER) and often result in constitutive activation of the ER. DBD, DNA-binding domain.

Back to article page